SCHEMBL4869247

SCHEMBL4869247

CC(C)(C=O)n1cnc(-c2cccnc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 10/20 0.59
CYP2C19 P33261 5/20 0.59
CYP2E1 P05181 4/20 0.59
CYP2C9 P11712 4/20 0.59
CYP2B6 P20813 4/20 0.59
CYP3A4 P08684 7/20 0.56
CYP2D6 P10635 2/20 0.48
KIF11 P52732 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.42
HSP90AA1 P07900 2/20 0.42
HSP90AB1 P08238 2/20 0.42
ALK Q9UM73 1/20 0.41
CYP1A2 P05177 3/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
CYP19A1 P11511 1/20 0.41
ALDH1A1 P00352 2/20 0.40
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5507651 0.85 CYP2A6 (0.56) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL5505212 0.79 CYP2A6 (0.68) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL4864745 0.79 CYP2A6 (0.52) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL17688341 0.77 CYP2A6 (0.55) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL4870330 0.76 CYP2A6 (0.52) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL4862008 0.75 CYP2A6 (0.54) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL3644924 0.74 CYP2A6 (1.00) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL4870983 0.72 CYP2A6 (0.48) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL7735787 0.72 CYP2A6 (0.48) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL3604362 0.72 CYP2A6 (1.00) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332476-B2 Pyridyl substituted ketolide antibiotics NOVARTIS AG (CH) 2008-02-19 US disclosed
US-7332476-B2 Pyridyl substituted ketolide antibiotics NOVARTIS AG (CH) 2008-02-19 US disclosed
US-7332476-B2 Pyridyl substituted ketolide antibiotics NOVARTIS AG (CH) 2008-02-19 US disclosed
US-20050009764-A1 Pyridyl substituted ketolide antibiotics CHIRON CORPORATION (US) 2005-01-13 US disclosed
US-6756359-B2 ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS CHIRON CORPORATION 2004-06-29 US disclosed
US-20030125266-A1 C12 Modified erythromycin macrolides and ketolides having antibacterial activity CHU DANIEL (US) 2003-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009764-A1 Pyridyl substituted ketolide antibiotics PKLR, KHK, PGD CYP2A6 57/4885CYP2C19 9/4885CYP2E1 323/4885
US-20030125266-A1 C12 Modified erythromycin macrolides and ketolides having antibacterial activity MRPL21, CYP51A1, CEL CYP2A6 68/4885CYP2C19 30/4885CYP2E1 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.